<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In addition to its well-known erythropoetic effect, erythropoietin (EPO) has also been shown to be neuroprotective in various animal models </plain></SENT>
<SENT sid="1" pm="."><plain>In contrast to EPO, carbamylated EPO (CEPO) does not bind to the EPO receptor on UT7 cells or have any haematopoietic/proliferative activity on these cells </plain></SENT>
<SENT sid="2" pm="."><plain>In vivo studies in mice and rats showed that even high doses of CEPO for long periods are not erythropoietic </plain></SENT>
<SENT sid="3" pm="."><plain>However, in common with EPO, CEPO does inhibit the <z:mpath ids='MPATH_3'>apoptosis</z:mpath> associated with <z:chebi fb="6" ids="14321,29987">glutamate</z:chebi> toxicity in hippocampal cells </plain></SENT>
<SENT sid="4" pm="."><plain>Like EPO, CEPO is neuroprotective in a wide range of animal models of neurotoxicity: middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> model of ischaemic <z:hpo ids='HP_0001297'>stroke</z:hpo>, <z:e sem="disease" ids="C0338562" disease_type="Disease or Syndrome" abbrv="">sciatic nerve compression</z:e>, spinal cord <z:hpo ids='HP_0000716'>depression</z:hpo>, experimental autoimmune <z:mp ids='MP_0006082'>encephalomyelitis</z:mp> and peripheral <z:e sem="disease" ids="C0011882" disease_type="Disease or Syndrome" abbrv="">diabetic neuropathy</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>To date, EPO and CEPO have been exciting developments in the quest for the treatment of various types of neurotoxicity </plain></SENT>
<SENT sid="6" pm="."><plain>The development of CEPO should continue </plain></SENT>
</text></document>